Immunotherapy duo aims to wipe out hidden colorectal cancer cells
NCT ID NCT07551596
First seen Apr 28, 2026 · Last updated May 02, 2026 · Updated 1 time
Summary
This study tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny traces of cancer DNA from the blood of people with stage II or III colorectal cancer after standard treatment. About 20 adults whose blood still shows cancer DNA but no visible tumors on scans will receive the drug combination. The goal is to see if the treatment can eliminate remaining cancer cells and lower the risk of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.